Imiquimod: in superficial basal cell carcinoma

Area of Science:

• Dermatology
• Oncology
• Immunology

Background:

• Superficial basal cell carcinoma (BCC) is a common skin cancer.
• Imiquimod 5% cream is a novel topical treatment option for adults with superficial BCC.
• The precise mechanism of action for imiquimod in superficial BCC is not fully elucidated but involves immune modulation.

Purpose of the Study:

• To evaluate the efficacy and safety of topical imiquimod 5% cream for treating superficial BCC in adults.
• To compare the clearance rates of imiquimod versus vehicle treatment.
• To assess the long-term efficacy of imiquimod treatment for superficial BCC.

Main Methods:

• Two large, well-designed clinical trials were conducted.
• Adult patients with superficial BCC applied imiquimod 5% cream or vehicle for 6 weeks.
• Treatment regimens included application five or seven times per week.

Main Results:

• Composite clearance rates at 12 weeks post-treatment were 75% (5x/week), 73% (7x/week), and 2% (vehicle).
• Long-term follow-up showed a 90% clinical clearance rate at 12 weeks and 84% at 1 year for imiquimod (5x/week).
• Common adverse events included application site reactions like erythema, erosion, and crusting, which correlated with treatment response.

Conclusions:

• Topical imiquimod 5% cream demonstrates significant efficacy in achieving clinical and histologic clearance of superficial BCC.
• The treatment is well-tolerated, with manageable local skin reactions.
• Imiquimod offers a promising therapeutic option for superficial BCC, supported by robust clinical trial data.